Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elsa Quintana

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Science Translational Medicine|November 9, 2012
Human melanoma metastasis in NSG mice correlates with clinical outcome in patientsElsa Quintana, Elena Piskounova, Mark Shackleton, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 11, 2009
iNOS-derived nitric oxide mediates the increase in TFF2 expression associated with gastric damage: role of HIF-1Dolores Ortiz-Masiá, Carlos Hernández, Elsa Quintana, et al.
Nature Communications|August 23, 2016
Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanomaUgur Eskiocak, Vijayashree Ramesh, Jennifer G Gill, et al.
The Journal of Investigative Dermatology|March 12, 2014
Merkel cell carcinoma dependence on bcl-2 family members for survivalMonique E Verhaegen, Doris Mangelberger, Jack W Weick, et al.
Nature Communications|September 30, 2016
Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanomaUgur Eskiocak, Vijayashree Ramesh, Jennifer G Gill, et al.
Nature Communications|September 25, 2024
Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockadePanayiotis Anastasiou, Christopher Moore, Sareena Rana, et al.
Cancer Research|May 1, 2020
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive EnvironmentElsa Quintana, Christopher J Schulze, Darienne R Myers, et al.
Cancer Discovery|March 9, 2025
T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDACMargo I Orlen, William P Vostrejs, Rina Sor, et al.
Cancer Immunology Research|November 4, 2025
RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant MelanomaLarissa Anastacio Da Costa Carvalho, Nataliya Tovbis Shifrin, Manali S Phadke, et al.
Frontiers in Immunology|November 2, 2020
Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor ImmunityDarienne R Myers, Clare L Abram, David Wildes, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Science Translational Medicine|November 9, 2012
Human melanoma metastasis in NSG mice correlates with clinical outcome in patientsElsa Quintana, Elena Piskounova, Mark Shackleton, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 11, 2009
iNOS-derived nitric oxide mediates the increase in TFF2 expression associated with gastric damage: role of HIF-1Dolores Ortiz-Masiá, Carlos Hernández, Elsa Quintana, et al.
Nature Communications|August 23, 2016
Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanomaUgur Eskiocak, Vijayashree Ramesh, Jennifer G Gill, et al.
The Journal of Investigative Dermatology|March 12, 2014
Merkel cell carcinoma dependence on bcl-2 family members for survivalMonique E Verhaegen, Doris Mangelberger, Jack W Weick, et al.
Nature Communications|September 30, 2016
Erratum: Synergistic effects of ion transporter and MAP kinase pathway inhibitors in melanomaUgur Eskiocak, Vijayashree Ramesh, Jennifer G Gill, et al.
Nature Communications|September 25, 2024
Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockadePanayiotis Anastasiou, Christopher Moore, Sareena Rana, et al.
Cancer Research|May 1, 2020
Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive EnvironmentElsa Quintana, Christopher J Schulze, Darienne R Myers, et al.
Cancer Discovery|March 9, 2025
T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDACMargo I Orlen, William P Vostrejs, Rina Sor, et al.
Cancer Immunology Research|November 4, 2025
RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant MelanomaLarissa Anastacio Da Costa Carvalho, Nataliya Tovbis Shifrin, Manali S Phadke, et al.
Frontiers in Immunology|November 2, 2020
Shp1 Loss Enhances Macrophage Effector Function and Promotes Anti-Tumor ImmunityDarienne R Myers, Clare L Abram, David Wildes, et al.
Pageof 4